P53.09 Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients

Abstract

KIT was identified as a proto-oncogene mutated or up-regulated in different types of cancers. However, it is unlikely that KIT inhibitors will be effective for lung cancer patients. Analysis of activating KIT mutations in lung cancer will be helpful to explain the above issue. Furthermore, previous studies showed that an activating KIT mutation could induce crizotinib resistance in ROS1-positive lung cancer. To assess the probability of tyrosine kinase inhibitors (TKIs) resistance induced by activating KIT mutations, we explored co-occurring activating alterations of KIT with other tyrosine kinase genes in a large cohort of Chinese lung cancer patients.